Prevalence of hyperuricaemia in an Eastern Chinese population: a cross-sectional study
Prevalence of hyperuricaemia in an Eastern Chinese population: a cross-sectional study
复制标题
中国东部人群高尿酸血症的患病率:一项横断面研究
DOI:
10.1136/bmjopen-2019-035614
复制
发表时间:
2020-01-01
期刊:
影响因子:
2.9
通讯作者:
Lu, Yingli
中科院分区:
文献类型:
--
作者:
Han, Bing;Wang, Ningjian;Lu, Yingli
Objectives In the past decade, China has been characterised by large-scale urbanisation as well as rapid economic growth. The aim of this study was to further investigate the prevalence of hyperuricaemia (HUA) in an Eastern Chinese population. Design Cross-sectional study. Setting Survey of Prevalence in East China of Metabolic Diseases and Risk Factors China study. Participants In this study, 12 770 residents from 22 sites in Eastern China were recruited. Finally, 9225 subjects were included. Main outcome measures The serum levels of uric acid (UA), fasting plasma glucose (FPG), glycated haemoglobin and other metabolic parameters were tested. Waist circumference, weight, height and blood pressure were also measured. Questionnaires regarding smoking, drinking, education were collected from the subjects. HUA was defined as serum UA >420 µmol/L for men and >360 µmol/L for women. Results The prevalence of HUA in this Eastern Chinese population was 11.3% (9.9, 12.7) overall, 20.7% (17.7, 23.7) in men and 5.6% (4.3, 6.7) in women. The prevalence of HUA in urban subjects was higher than that in rural subjects (12.9 vs 10.8%, p<0.01). The prevalence of HUA was negatively and positively associated with age in men and women, respectively. Residents with high body mass index levels had a higher prevalence of HUA. In the logistic regression analysis, male sex, urban residency, total cholesterol, triglyceride, overweight, obesity, systolic blood pressure and low economic status were independently correlated with HUA. Conclusions The estimated prevalence of HUA in this Eastern Chinese population was 11.3% (9.9, 12.7) overall and 20.7% (17.7, 23.7) and 5.6% (4.3, 6.7) in men and women, respectively. HUA has gradually become an important public health issue in China. Trial registration number ChiCTR-ECS-14005052.